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INTRODUCTION
Histoincompatibility is a dominant risk factor for adverse
outcomes after unrelated-donor marrow transplantation using
cyclosporine-based graft-versus-host disease (GVHD) pro-
phylaxis [1-4]. In the earliest studies using largely sero l o g i c
typing, major or cro s s - reactive antigen mismatches in the
major histocompatibility complex (MHC) were associated
with decreased survival, especially for adults with good-risk
leukemia, and a modest increase in risk for severe acute
GVHD compared with patients with serologically matched
donors. With the advent of molecular typing, the impact of
allelic mismatches at MHC class II loci on transplantation
outcomes has been evaluated more fully in sero l o g i c a l l y
matched patient-donor pairs. Allelic incompatibilities at
human leukocyte antigen (HLA)-DRB1 or HLA-DQB1 were
associated with an increased risk of grades 3 to 4 acute GVHD
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ABSTRACT
One hundred patients of median age 34 years (range, 14-53) received bone marrow transplants from unre l a t e d
donors serologically matched for human leukocyte antigen HLA-A, HLA-B, and HLA-DR using tacrolimus and
m i n i m e t h o t rexate for prevention of acute graft-versus-host disease (GVHD). Sixty-eight patient-donor pairs had
allelic matches at HLA-DRB1 and HLA-DQB1, 20 pairs had a single mismatch at HLA-DRB1 or HLA-DQB1, and
12 were mismatched at both HLA-DRB1 and HLA-DQB1. Minimum follow-up time was 6 months. Grades 2 to 4
GVHD occurred in 43% of patients with matched donors, 69% with single allele–mismatched donors, and 71% with
double allele–mismatched donors; grades 3 to 4 GVHD occurred in 22%, 43%, and 64%, re s p e c t i v e l y. On multivari-
ate analysis, the relative risk of grades 2 to 4 GVHD was 2.2 (95% CI, 1.1-4.5; P = .03) with a single allele mismatch
and 2.7 (95% CI, 1.2-6.0; P = .02) with a double allele mismatch. The relative risks of grades 3 to 4 GVHD were 3.0
(95% CI, 1.2-7.6; P = .02) and 5.0 (95% CI, 1.9-12.6; P = .001), re s p e c t i v e l y. Day 100 tre a t m e n t - related mort a l i t y
was also adversely affected by allelic mismatching, occurring in 21% of those with matched donors, 50% with single
allele–mismatched donors, and 42% with double allele–mismatched donors (P = .02), but overall survival at day 180
did not differ significantly among the 3 groups. Ta c rolimus does not abrogate the adverse impact of allele mis-
matching at HLA-DRB1 and HLA-DQB1 on the risk of moderate-to-severe acute GVHD.
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[5-10], an increased risk of tre a t m e n t - related mort a l i t y
[5,7,8,10], and in some cases, a reduction in overall or disease-
f ree survival [5,7,8,11]. To date, only T-cell depletion has been
shown to abrogate the increased risk of acute GVHD associ-
ated with MHC class II allelic mismatches [8,12].
Ta c rolimus is a naturally occurring macrolide lactone
with immunosuppressive activity [13,14]. When combined
with its cytosolic re c e p t o r, FK506-binding pro t e i n ,
t a c rolimus blocks the action of calcineurin in the calcium-
dependent signal transduction pathway, including transcrip-
tion of early T-cell activation genes. Although the mechanism
of action is the same as that of the cyclosporine-cyclophilin
complex, tacrolimus is more than 100 times more potent than
cyclosporine in its immunosuppressive pro p e rties. In a dog
model, the combination of tacrolimus and methotrexate was
e ffective in inducing tolerance in unrelated dog leukocyte
antigen–nonidentical marrow graft recipients, with a tre n d
for improved survival relative to dogs treated with cyclo-
sporine and methotrexate [15]. This suggests that tacro l i m u s
may be more potent than cyclosporine for prevention of
GVHD with mismatched unrelated donors.
In clinical studies, we [16] and other investigators
[17,18] have re p o rted that the combination of tacro l i m u s
and methotrexate is active for prevention of acute GVHD
after unrelated-donor marrow transplantation; in a random-
ized trial, the risk of GVHD was significantly less with
tacrolimus/methotrexate than with cyclosporine/methotrex-
ate in this setting [19]. More o v e r, on re t rospective evalua-
tion, we found that the rate of moderate-to-severe GVHD
using tacro l i m u s / m e t h o t rexate after HLA-nonidentical
m a rrow transplantation was similar to that with cyclo-
sporine and partial T-cell depletion [20]. We there f o re
sought to determine whether tacrolimus was suff i c i e n t l y
potent to overcome the increased risk of acute GVHD




From January 1994 through July 1998, 100 adults with
u n related donors serologically matched for HLA-A, HLA-B ,
and HLA-DR were eligible for transplantation using a mye-
loablative preparative regimen with tacrolimus and minidose
m e t h o t rexate for prevention of acute GVHD. DRB1 and
DQB1 allele typing was perf o rmed, but matching at the
allele level was not an eligibility requirement. The primary
treatment and GVHD prophylaxis protocols were approved
by the Institutional Review Board of the University of Texas
M.D. Anderson Cancer Center, and each recipient provided
written informed consent.
Assessment of HLA Alleles
HLA typing was performed by standard serologic tech-
niques, and polymerase chain reaction with sequence-specific
primers was used to subtype HLA-DRB1 and HLA-DQB1
[21]. For purposes of this study, a molecular mismatch refers
to an allelic disparity identified by high-resolution typing
but not by serologic typing; a minor mismatch refers to a
s e rologically cro s s - reactive antigen; and a major mismatch
refers to a serologically distinct antigen as defined by the
Eleventh International Histocompatibility Workshop [22].
Since eligibility re q u i red serologic matching at HLA-DR,
no patient-donor pair had more than a molecular mismatch
at HLA-DRB1. Twelve patients were classified as having a
mismatch in both HLA-DRB1 and HLA-DQB1 (double
mismatch); in this group, in addition to the molecular
m i smatches at HLA-DRB1, 1 patient had a molecular mis-
match at HLA-DQB1, 7 had a minor mismatch at HLA-
DQB1, and 4 had a major mismatch at HLA-DQB1.
Twenty patients were classified as having a single mismatch
in either HLA-DRB1 or HLA-DQB1; of these, 12 had a
single molecular mismatch at HLA-DRB1, 3 had a single
molecular mismatch at HLA-DQB1, 4 had a single minor
mismatch at HLA-DQB1, and 1 had a single major mis-
match at HLA-DQB1. The other 68 patients were classified
as having a molecular (allele) match at HLA-DRB1 and
HLA-DQB1. On re t rospective review of the HLA typing,
1 patient had a minor mismatch in HLA-A but was molecu-
larly matched at HLA-DRB1 and HLA-DQB1. Because the
analysis was performed on an intent-to-treat basis, the latter
patient was classified as molecularly matched and assessed
for all study outcomes.
Transplantation and Suppor t i v e Care
S t a n d a rd total-body irradiation–based or busulfan-
based preparative regimens were used for 91 patients
[16,23]. One patient received carmustine (BCNU), etopo-
side, cytarabine, and melphalan (BEAM) [23] as the prepara-
tive regimen, 4 patients received fludarabine 30 mg/m2
intravenously (IV) on days –5 to –2 in addition to BEAM
(FBEAM), and 4 patients received fludarabine, BCNU,
cytarabine, and melphalan (FBAM) at the same dosages.
Day 0 is the day of transplantation. Details of support i v e
care measures have been published [16].
M a rrow was harvested and processed for ABO incom-
patibility by standard measures when necessary. None of the
transplants was depleted of T cells. Marrow harvests con-
tained a median total nucleated cell dose of 3.95 3 108/kg
(range, 1.1-6.8 3 108/kg). Filgrastim 5 µg/kg per day subcu-
taneously was administered from day 7 after transplantation
t h rough engraftment for all patients except 1 patient who
had a history of an adverse reaction to filgrastim.
GVHD Pr o p h ylaxis and Tr e a t m e n t
M e t h o t rexate 5 mg/m2 IV was given on days 1, 3, 6, and
11. The dosage was reduced or omitted for severe mucositis
(oral ulceration or significant edema), reduction in cre a t i n i n e
clearance of more than 50%, or weight gain of more than
10 kg. Ta c rolimus was administered at 0.03 mg/kg (ideal body
weight) per day IV by continuous infusion from day –2. After
engraftment when the patient was able to take medications
o r a l l y, the 24-hour IV dose of tacrolimus was converted fro m
1 to 4, given orally in a twice-daily divided dose until tapere d
o ff by 6 to 8 months after transplantation. Dosages were
adjusted to maintain whole-blood steady-state or trough levels
at 5 to 15 ng/mL. Ta c rolimus was discontinued or re d u c e d
when blood levels were elevated or the serum creatinine was
i n c reased [24]. Patients were observed prospectively for devel-
opment of acute GVHD. The diagnosis of GVHD was based
on clinical evidence with histologic confirmation [25], and
GVHD was graded according to the consensus criteria [26].
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Patients who developed grade 2 to 4 GVHD were tre a t e d
with methylprednisolone at 0.5 mg/kg IV every 6 hours.
Study Definitions
Disease status was categorized as low, intermediate, or
high risk according to the International Bone Marrow Tr a n s-
plant Registry (IBMTR) criteria [27]. Neutrophil re c o v e ry
was defined as the first of 3 consecutive days that the
absolute neutrophil count exceeded the target number (0.5
or 1.0 3 1 09/L), and platelet re c o v e ry was defined as the day
that the platelet count exceeded the target number (20 or
50 3 1 09/L) with no platelet transfusions during the follow-
ing week. Early preparative re g i m e n - related toxicity (RRT )
was graded according to the criteria of Bearman et al. [28].
Statistical Considerations
At the time of analysis, median time from transplanta-
tion was 31 months (range, 6-60). Actuarial estimates of the
risk of GVHD and the times to engraftment, discharge, and
death were calculated according to the method of Kaplan
and Meier [29]. The log-rank test was used to compare
actuarial outcomes among groups. For the multivariate
analysis of risk factors for acute GVHD, a proportional haz-
ards model was fitted using a backward-stepping procedure,
with low tacrolimus blood level entered as a time-dependent
covariate. Ta c rolimus blood levels from the first 40 days
after transplantation were used in this analysis. Va r i a b l e s
achieving a significance of 0.1 were retained in the final
model. Assessment of diff e rences among groups was made
using the log-likelihood ratio or Fisher exact for categorical
data and the Kruskal-Wallis analysis of variance for ordinal
data. A 2-sided P value <.05 was considered significant.
These analyses were perf o rmed using Stata Release 5.0
(Stata Corporation, College Station, TX).
RESULTS
Patient Characteristics
Sixty-two males and 38 females of median age 34 years
(range, 14-53) were treated. Each patient had a hematologic
malignancy of low (21%), intermediate (18%), or high
(61%) risk, and 44% were refractory to conventional ther-
apy. Two patients were being treated for relapse after prior
unrelated-donor marrow transplantation using cyclosporine
for GVHD prophylaxis, and 5 patients were being tre a t e d
after autologous transplantation. The median donor age was
34 years (range, 19-56). Of the patient-donor pairs, 17%
were female donor to male recipient, and 10% were parous
Table 1. Patient and Donor Characteristics*
HLA-DRB1 and HLA-DQB1 Mismatch †
None Single Double
Number of patients 68 20 12 
Median age (range) 34 y (14-49) 34 y (16-53) 29 y (22-49)
Patient sex (male/female) 41/27 12/8 9/3
Diagnosis
Acute leukemia
Remission 1 3 0 0
Remission ≥2 5 3 0
Relapse 17 5 5
Myelodysplastic syndrome 3 0 0
Chronic myelogenous leukemia
Chronic phase 1 8 4 1
Chronic phase >2 3 1 0
Accelerated phase 19 3 3
Blast crisis 1 1 1
Myeloproliferative disorder 1 0 0
Chronic lymphocytic leukemia 3 2 0
Malignant lymphoma 5 1 2
Resistant to therapy 33 7 4
Prior transplantation 4 1 2
Preparative regimen
Cyclophosphamide/TBI 3 2 0
Thiotepa/cyclophosphamide/TBI 49 15 6
Etoposide/cyclophosphamide/TBI 1 0 1
Thiotepa/busulfan/cyclophosphamide 7 2 5
Carmustine/cytarabine/melphalan ± etoposide ± fludarabine 8 1 0
Median marrow cell dose 310 8/kg (range) 4.1 (1.2-6.8) 3.5 (1.1-5.0) 4.0 (2.3-5.3)
Donor median age (range) 35 y (21-56) 34 y (19-45) 29 y (19-52)
Donor sex (male/female) 41 / 27 10 / 10 7 / 5
Parous donor-to-male recipient 5 2 3
Patient-donor pair CMV-seronegative 16 1 3
*CMV indicates cytomegalovirus; and TBI, total body irradiation.
†Number of patients unless indicated otherwise.
193B B & M T
female donor to male recipient. Twenty patients were
c y t o m e g a l o v i ru s - s e ronegative with cytomegaloviru s -
seronegative donors. Patient and donor characteristics cate-
gorized by molecular mismatch are listed in Table 1. No
significant differences were found in the demographic char-
acteristics among groups.
Acute GVHD
For all patients, the actuarial risk of grades 2 to 4
GVHD was 51% (95% CI, 41%- 62%), and that of grades 3
to 4 GVHD was 31% (95% CI, 22%-41%). On univariate
analysis, the degree of HLA class II mismatch (Figure 1) and
the diagnosis were significant risk factors for grades 2 to 4
GVHD, whereas the degree of HLA class II mismatch (Fig-
ure 1) and a tacrolimus blood level <5 ng/mL were signifi-
cant risk factors for grades 3 to 4 GVHD (Table 2).
Multivariate analysis showed a stepwise increase in risk
of GVHD when patients were categorized by degree of HLA
class II mismatch. Compared with patients with donors mol-
ecularly matched at both HLA-DRB1 and HLA-DQB1, the
relative risk of grades 2 to 4 GVHD was 2.2 with a single
mismatch at either locus and 2.7 with a mismatch at both loci
( Table 3). The diff e rences in risk were even greater when
grades 3 to 4 GVHD were evaluated; the relative risk was 3.0
with a single mismatch and 5.0 with a mismatch at both loci
( Table 3). When single mismatches at HLA-DRB1 or HLA-
DQB1 were entered into the final model separately, a single
mismatch at HLA-DRB1 still conferred a significantly
higher risk of grades 2 to 4 GVHD (relative risk 3.4; 95% CI
1.6-7.5; P = .002) and grades 3 to 4 GVHD (relative risk 4.7;
95% CI 1.8-12.6; P = .002). A single mismatch at HLA-
DQB1 did not remain in the model (ie, P > .1), but the num-
ber of patients in this group was small.
An increasing pro p o rtion of deaths due to GVHD
within the first 180 days after transplantation was found
when patients were assessed by degree of HLA class II mis-
match (21% with no mismatch, 30% with a single mis-
match, and 42% with a double mismatch), but the difference
was not significant (P = .25).
E a r l y Transplantation Outcomes
For all patients, 89% had grades 2 to 4 RRT, 12% had
grades 3 to 4 RRT, and 17% had a cumulative RRT score >7 .
No significant diff e rences in RRT were found among gro u p s
categorized by degree of HLA class II mismatch (Table 4).
The median duration of filgrastim use was 11 days (range,
0-37). Three evaluable patients did not achieve neutro p h i l
recovery within 30 days. One had an autoimmune n e u t ro p e-
nia [30], the second had persistent relapse, and the third
exhibited graft rejection. The patient with graft re j e c t i o n
had been conditioned with BEAM and received marro w
from a donor with a minor mismatch at HLA-DQB1. The
median times to hematologic recovery were 16 days ( r a n g e ,
10-35) to an absolute neutrophil count >0.5 3 1 09/L, 17 days
(range, 10-36) to an absolute neutrophil count >1.0 3 109/ L ,
24 days (range, 12-98) to platelets >20 3 109/L, and 32 days
(range, 15-100) to platelets >50 3 1 09/L. No significant
d i ff e rences in hematologic re c o v e ry were found among
g roups, although patients with no mismatches at HLA-
DRB1 or HLA-DQB1 tended to have earlier platelet recov-
ery times (Table 4).
Day 100 treatment-related mortality was 29% (95% CI,
22%-40%). A significant diff e rence in tre a t m e n t - re l a t e d
m o rtality was evident when patients were compared by
degree of HLA class II mismatch (Table 4). Those with no
mismatch at HLA-DRB1 or HLA-DQB1 had the lowest
day 100 tre a t m e n t - related mortality rate (21%). Day 100
treatment-related mortality rates were 38% for those with a
single mismatch at HLA-DQB1 and 58% for those with a
single mismatch at HLA-DRB1 (P = .65). The causes of
death within 180 days after transplantation are listed in
Table 5. No significant diff e rence in day 180 survival was
identified when patients were categorized by degree of HLA
class II mismatch (P = .31).
Figure 1 . Actuarial estimates of grades 2-4 (A) and grades 3-4 (B) acute graft-versus-host disease with no mismatch (solid line), 1 mismatch (dashed




Ta c rolimus is a potent immunosuppressive drug that
has been shown to be more effective than cyclosporine for
p revention of acute GVHD after unrelated-donor marro w
transplantation [19]. Using tacrolimus and minimethotre x-
ate, we have found that only 22% of unrelated-donor mar-
row transplant recipients develop severe acute GVHD
when recipient and donor are molecularly matched for
HLA-DRB1 and HLA-DQB1. This low rate of severe
acute GVHD is similar to that re p o rted by Nash et al. [17]
using tacrolimus with standard methotrexate, and some-
what lower than the 32% to 48% rates re p o rted with
cyclosporine and methotrexate for molecularly matched
patient-donor pairs [3-5]. However, we also found that the
risk of severe GVHD increased incremental ly  with
i n c reasing mismatches at HLA-DRB1 and HLA-DQB1,
Table 2. Univariate Analysis of Risk Factors for Acute Graft-Versus-Host Disease (GVHD)*
Grades 2-4 GVHD Grades 3-4 GVHD
Factor Number of Patients % (95% CI) P Value % (95% CI) P Value
HLA-DRB1 or -DQB1 mismatch
None 68 43 (32-57) .02 22 (14-34) .003
Single 20 69 (45-90) 43 (23-71)
Double 12 71 (44-93) 64 (37-89)
Age (y)
<25 19 69 (46-88) .4 46 (26-72) .09
25-34 35 46 (31-65) 27 (15-46)
35-44 34 48 (32-67) 37 (22-57)
>44 12 44 (21-77) 0
Diagnosis
AML/MDS 23 14 (5-37) .002 10 (2-34) .1
ALL 18 63 (40-86) 31 (14-60)
CML 46 58 (44-73) 38 (26-54)
CLL/NHL 13 76 (47-96) 35 (14-69)
Disease risk group
Low 21 68 (48-87) .1 39 (22-63) .5
Intermediate 18 47 (27-72) 35 (18-62)
High 61 45 (33-60) 26 (16-40)
Female donor/male recipient
No 83 49 (38-61) .6 30 (21-42) .9
Yes 17 59 (37-83) 33 (15-62)
Parous donor/male recipient
No 90 52 (41-63) .7 30 (21-42) .9
Yes 10 44 (19-79) 33 (12-72)
Preparative regimen
No TBI 23 31 (16-54) .1 21 (8-48) .2
TBI 77 56 (45-68) 34 (24-46)
Marrow cell dose
>3.65 3 10 8/kg 58 56 (43-70) .2 38 (26-53) .09
<3.65 3 108/kg 42 44 (30-61) 21 (11-37)
Tacrolimus blood level
≥5 ng/mL 35 (22-53) .1 17 (7-36) .02
<5 ng/mL 67 57 (45-71) 39 (28-53)
≥10 ng/mL 25 (10-56) .7 35 (23-50) .4
<10 ng/mL 100 51 (40-62) 26 (15-42)
Methotrexate doses
Complete 66 52 (41-65) .6 32 (22-45) .7
Incomplete 34 48 (31-68) 27 (14-46)
*ALL indicates acute lymphocytic leukemia; AML, acute myelocytic leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; CML, chronic myeloge-
nous leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; and TBI, total-body irradiation.
Table 3. Multivariate Analysis of Risk Factors for Acute Graft-Versus-
Host Disease (GVHD)*
Relative Risk
Outcome/Factor (95% CI) P
Grades 2-4 GVHD
Double HLA-DRB1/DQB1 mismatch 2.7 (1.2-6.0) .02
Single HLA-DRB1 or -DQB1 mismatch 2.2 (1.1-4.5) .03
Tacrolimus level <5 ng/mL 1.7 (0.93-3.1) .09
AML/MDS 0.2 (0.1-0.5) .002
Grades 3-4 GVHD
Double HLA-DRB1/DQB1 mismatch 5.0 (1.9-12.6) .001
Single HLA-DRB1 or -DQB1 mismatch 3.0 (1.2-7.6) .02
Tacrolimus level <5 ng/mL 3.1 (1.2-7.7) .02
Cell dose >3.65 3 10 8/kg 2.3 (1.0-5.3) .05
*AML indicates acute myelocytic leukemia; CI, confidence interval; and MDS,
myelodysplastic syndrome.
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suggesting that tacrolimus is not as effective as T- c e l l
depletion in abrogating the effect of molecular MHC class
II incompatibilities on the risk of GVHD after unre l a t e d -
donor marrow transplantation [8,12]. We cannot exclude
the possibility that the risk of acute GVHD might be lower
if standard methotrexate had been used rather  than
m i n i m e t h o t rexate, but compliance with methotrexate dos-
ing has not been identified as an independent risk factor
for acute GVHD in unrelated-donor marrow transplanta-
tion [5,6], and in a nonrandomized multicenter study, the
rates of acute GVHD did not differ between the gro u p s
receiving minimethotrexate and standard methotrexate in
combination with tacrolimus [31].
The current recommended therapeutic target range for
tacrolimus is 10 to 20 ng/mL [32]. Since 10 ng/mL was the
lower limit used in the prospective c linical trials of
tacrolimus for unrelated-donor marrow transplantation [19],
efficacy with lower levels could not be established by retro-
spective analysis. In this study, we used a target range of 5 to
15 ng/mL, and all patients had at least 1 tacrolimus level less
than 10 ng/mL within 40 days after transplantation. When
e n t e red into the multivariate analysis as a time-dependent
cofactor, a tacrolimus level less than 10 ng/mL was not an
independent risk factor for acute GVHD. By contrast, a
1 . 7 -fold increase in grades 2 to 4 GVHD and a 3.1-fold
i n c rease in grades 3 to 4 GVHD occurred when the
t a c rolimus level was less than 5 ng/mL, re g a rdless of the
degree of histoincompatibility. These results clearly demon-
strate that a tacrolimus whole blood level less than 5 ng/mL
in the early posttransplantation period is subtherapeutic.
Although the risk of acute GVHD is known to incre a s e
with the number of disparate class II loci [9,33], whether
incompatibility at a specific locus results in a greater risk of
GVHD has not been firmly established. Alloreactive T cells
may be stimulated directly by the allogeneic MHC mole-
cule with or without additional peptide, or indirectly by
p resentation of peptides processed from the allogeneic
MHC molecule, and animal studies suggest that allore c o g-
nition is directed primarily against the intact allogeneic
molecule rather than allogeneic MHC-derived peptides
[34]. To evaluate this question in humans, van Els et al. [35]
examined alloreactive cells from patients with acute GVHD
and found that responses against minor antigens were
restricted predominantly by HLA-DR rather than HLA-
DP or HLA-DQ [35]. Consistent with this re p o rt, we
found that within the single mismatch group, a disparity at
HLA-DRB1 conferred a greater risk of GVHD than a sin-
gle mismatch at HLA-DQB1. Our results contrast with the
study of Petersdorf et al. [6] in which a single HLA-DQB1
mismatch conferred a higher relative risk of GVHD than a
single HLA-DRB1 mismatch. However, we caution that in
our series the number of patients with a single mismatch at
HLA-DQB1 was small, and in agreement with Petersdorf
et al. [6], the risk of GVHD may depend on the nature as
well as the number of disparities rather than just the pre s-
ence or absence of histoincompatibility.
Our results may also be confounded by molecular mis-
matching at other MHC class I or II loci. A high pre v a l e n c e
of HLA-DP disparity has been re p o rted among HLA-A–,
HLA-B–, HLA-DRB1–, and HLA-DQB1–matched re c i p i-
ent-donor pairs, occurring in more than 80% of such cases
[36,37]. Although HLA-DP incompatibility did not incre a s e
GVHD risk in patients with class I serologically matched
donors [36], statistically only a strong effect could be detected
when the number of patients studied is relatively small and
the prevalence of the covariable so extreme. In contrast,
molecular disparities in MHC class I loci occur in 42% to
70% of HLA-A, HLA-B, and HLA-DRB1 sero l o g i c a l l y
matched pairs [37-41]. Although class I disparities are associ-
Table 5. Causes of Death Before Day 180 After Transplantation*
HLA-DRB1 and HLA-DQB1 Mismatch
None Single Double
Graft failure 0 0 0
Infection 6 2 0
GVHD ± infection 14 6 5
Relapse 8 2 0
Regimen toxicity 2 3 1
Other 1 0 0
Total 31 13 6
*GVHD indicates graft-versus-host disease.
Table 4. Effect of HLA Class II Mismatches on Transplant Outcomes*
HLA-DRB1 and HLA-DQB1 Mismatch
Outcome None Single Double P
Patients with maximum RRT Gr 2-4 (%) 59/68 (87%) 20/20 (100%) 10/12 (83%) .07 
Patients with maximum RRT Gr 3-4 (%) 6/68 (9%) 5/20 (25%) 1/12 (8%) .18
Patients with cumulative RRT ≥7 (%) 8/68 (9%) 6/20 (30%) 3/12 (25%) .14
Day ANC >0.5 3 10 9/L (range) 16 (10-35) 16 (12-23) 16 (14-21) .55
Day ANC >1.0 3 10 9/L (range) 17 (10-36) 18 (13-26) 17 (15-21) .39
Day platelets >20 3 10 9/L (range) 23 (12-98) 25 (19-69) 30 (20-142) .07
Day platelets >50 3 109/L (range) 28 (15-100) 36 (20-95) 38 (20-94) .35
Days filgrastim used (range) 11 (0-36) 11 (6-37) 10 (7-17) .87
Day of discharge (range) 25 (15-78) 33 (20-55) 26 (20-46) .06
Day 100 treatment-related mortality (95% CI) 21% (13-32) 50% (31-73) 42% (20-73) .02
*ANC indicates absolute neutrophil count; CI, confidence interval; and RRT, regimen-related toxicity.
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ated with an increased donor-antihost cytotoxic T-l y m p h o-
cyte precursor (CTLp) fre q u e n c y, suggesting a potential for
i n c rease in GVHD [39], the conclusions from analyses of the
e ffects of molecular MHC class I incompatibility on GVHD
in clinical studies using cyclosporine have been inconsistent
[10,33,42,43]. The comparative efficacy of tacrolimus with
MHC class I mismatches has yet to be determ i n e d .
A high marrow cell dose has been re p o rted to be associ-
ated with a lower rate of grades 3-4 GVHD [44], although
this finding has not been consistent [6]. In our study of
adult patients only, we found a trend for increased grades
3-4 GVHD with a higher marrow cell dose. The discre p-
ancy in results between studies may re flect a biological dif-
f e rence in risk factors for the diff e rent GVHD pro p h y l a x i s
regimens used. However, the analysis re p o rted by Sierr a
e t al. [44] was also confounded by the inclusion of both
adult and pediatric patients in the study, with the pediatric
patients, who were at lower risk for GVHD, having by far
the higher cell doses.
Early tre a t m e n t - related mortality in our patients was
also increased with the MHC class II disparities, but sur-
vival at day 180 was not affected. When molecular MHC
class II matching is used, others have re p o rted that surv i v a l
is improved after unrelated-donor marrow transplantation
l a rgely for those with early rather than advanced disease.
Most of the patients in our study had intermediate or
advanced disease, with relapse being the most import a n t
factor affecting long-term outcome in this group. Thus, the
lack of impact of MHC incompatibility on survival in our
study probably does not re flect the ability of tacrolimus to
eliminate the adverse effects of GVHD on long-term sur-
vival, but rather it is due to the high risk of relapse acro s s
the study gro u p s .
In summary, we have shown that allelic mismatching at
HLA-DRB1 and HLA-DQB1 coincide with an increase in
m o d e r a t e - t o - s e v e re acute  GVHD despite the use of
tacrolimus, a potent immunosuppressive drug. These results
suggest that more potent inhibition of early T-cell activation
is insufficient to overcome reactivity to MHC incompatibili-
ties. Whether this can be accomplished using 1 of the newer
immunosuppressive drugs with an alternative mechanism of
action remains to be determined.
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